Author: Ravi Shankar

Amsterdam, 25 September 2026 — AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) has published an Annex IX information document in connection with the secondary listing of its shares on the Frankfurt Stock Exchange pursuant to Article 1(5)(ba) of Regulation (EU) 2017/1129 (the Prospectus Regulation). The intention to apply for the listing on the Frankfurt Stock Exchange was announced on August 24, 2026.

The first day of trading on the Frankfurt Stock Exchange is expected to be September 30, 2026. The AMG shares will trade on the Frankfurt Stock Exchange under the ticker symbol “ADG”. As previously announced, AMG does not plan to issue or offer any new shares in connection with the secondary listing in Frankfurt. Euronext Amsterdam will continue to be AMG’s primary listing.

The Annex IX information document was also filed with the Dutch Authority for the Financial Markets (Stichting Autoriteit Financiële Markten) as competent authority under the Prospectus Regulation.

About AMG

AMG’s mission is to provide critical materials and related process technologies to advance a less carbon-intensive world. To this end, AMG is focused on the production and development of energy storage materials such as lithium, vanadium, and tantalum. In addition, AMG’s products include highly engineered systems to reduce CO₂ in aerospace engines, as well as critical materials addressing CO₂ reduction in a variety of other end use markets.

AMG’s Lithium segment spans the lithium value chain, reducing the CO₂ footprint of both suppliers and customers. AMG’s Vanadium segment is the world’s market leader in recycling vanadium from oil refining residues, spanning the Company’s vanadium, molybdenum, titanium, and chrome businesses. AMG’s Technologies segment is the established world market leader in advanced metallurgy and provides equipment engineering to the aerospace engine sector globally. It serves as the engineering home for the Company’s fast-growing LIVA batteries, NewMOX SAS formed to span the nuclear fuel market, and AMG’s mineral processing operations in antimony.

With approximately 3,500 employees, AMG operates globally with production facilities in Germany, the United Kingdom, France, the United States, China, Mexico, Brazil, and India, and has sales and customer service offices in Japan (www.amg-nv.com).

For further information, please contact:
AMG Critical Materials N.V.        +49 176 1000 73 14
Thomas Swoboda
tswoboda@amg-nv.com

Disclaimer

Certain statements in this press release are not historical facts and are “forward looking.” Forward looking statements include statements concerning AMG’s plans, expectations, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans and intentions relating to acquisitions, AMG’s competitive strengths and weaknesses, plans or goals relating to forecasted production, reserves, financial position and future operations and development, AMG’s business strategy and the trends AMG anticipates in the industries and the political and legal environment in which it operates and other information that is not historical information. When used in this press release, the words “expects,” “believes,” “anticipates,” “plans,” “may,” “will,” “should,” and similar expressions, and the negatives thereof, are intended to identify forward looking statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that the predictions, forecasts, projections and other forward-looking statements will not be achieved. These forward-looking statements speak only as of the date of this press release. AMG expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained herein to reflect any change in AMG’s expectations with regard thereto or any change in events, conditions, or circumstances on which any forward-looking statement is based.

Attachment

• Annex IX Information Document Press Release

Palm Beach, FL, Sept. 25, 2026 (GLOBE NEWSWIRE) — Pinnacle Acquisition Corporation (NYSE: PNAQ.U) (the “Company”) announced today that, commencing September 25, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and rights included in the units. The Class A ordinary shares and rights that are separated will trade on the New York Stock Exchange under the symbols “PNAQ” and “PNAQ.RT,” respectively. Those units not separated will continue to trade on the New York Stock Exchange under the symbol “PNAQ.U.”

“We believe our team’s experience building and scaling public-market platforms, executing strategic M&A and working across commercial and consumer finance positions us well to identify an exceptional company and help accelerate its next stage of growth,” said Steve Hudson, Co-founder, Chief Executive Officer and Chairman of Pinnacle Acquisition Corporation.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Pinnacle Acquisition Corporation

Pinnacle Acquisition Corporation is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, incorporated as a Cayman Islands exempted company and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

The Company intends to focus its search on partnering with management and owners of high-quality companies seeking an alternative to a traditional initial public offering in commercial finance, consumer finance and adjacent areas of the broader financial services ecosystem, including technology-enabled platforms and specialty finance businesses.

Pinnacle will seek to leverage its leadership team’s operating, M&A and capital markets experience, as well as its relationships with strategic acquirers, financial sponsors, investors and sector participants. The Company believes the current market environment, including growth in commercial and consumer finance, the importance of scaled specialty finance platforms and the shift toward diversified lending models, is creating attractive opportunities for partnership and value creation.

“Pinnacle was designed to bring experienced sponsorship, disciplined acquisition criteria and a partnership-oriented approach to companies that are ready for the public markets,” said Andrew Rechtschaffen, Co-founder and Director of Pinnacle Acquisition Corporation. “We currently see a compelling universe of potential opportunities across financial services and related technology-enabled sectors, and we are focused on finding a business where our team can help accelerate long-term value creation following the IPO.”

While the Company may pursue a business combination in any business or industry, it intends to focus its efforts on businesses with growth platforms, strong management teams and opportunities to drive value creation such as the ability to pursue further accretive acquisitions or capital structure optimization that can benefit from the business expertise of its Chief Executive Officer and Chairman, Steven K. Hudson, and its Chief Financial Officer, Jack Schneider. Andrew Rechtschaffen, Paul Stoyan, Karen Martin and Harry Brandler also serve as board members.

Forward-Looking Statements

This press release may include, and oral statements made from time to time by representatives of the Company may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to the Company or its management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the Securities and Exchange Commission (“SEC”). All subsequent written or oral forward-looking statements attributable to the Company or persons acting on its behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Company Contact

Jack Schneider
Chief Financial Officer
(561) 309-3447

• If approved, Joenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or more
• Decision follows recent approval of Joenja for children aged 4 to 11 years with APDS weighing at least 27 kg
• PDUFA target action date of January 30, 2027

Leiden, the Netherlands, September 25, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for lower doses of Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, for children aged 4 years and older who weigh between 13 kg and 27 kg with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. The application has been granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2027.

The sNDA is supported by positive data from an open-label, multinational, single-arm Phase III study in children aged 4 to 11 years, which showed improvements over 12 weeks in two clinically relevant hallmarks of the condition, reduced lymphadenopathy and increased naive B cells, together indicating correction of the underlying immune defect. The submission also includes additional scientific and clinical pharmacology assessments supporting the proposed dosing in lower-weight pediatric patients.

The FDA grants Priority Review to applications for medicines that, if approved, would offer significant improvements in effectiveness or safety of the treatment, prevention, or diagnosis of serious conditions.¹

“Today’s acceptance and Priority Review of our sNDA marks yet another important step in our efforts to expand access to Joenja for younger children living with APDS. Following the recent approval of Joenja for children aged 4 to 11 years weighing at least 27 kg, this review brings us closer to the possibility of reaching smaller children who currently are ineligible for treatment with Joenja,” said Anurag Relan, Chief Medical Officer of Pharming. “We look forward to working with the FDA and making Joenja available to eligible pediatric patients as efficiently as possible.”

The FDA approved Joenja for adults and pediatric patients aged 12 years and older with APDS in March 2023 and expanded the approval in September 2026 to include children aged 4 to 11 years weighing at least 27 kg.

About Activated Phosphoinositide 3-Kinase δ Syndrome (APDS) 
APDS is a rare primary immunodeficiency that was first characterized in 2013. APDS is caused by variants in either one of two identified genes known as PIK3CD or PIK3R1, which are vital to the development and function of immune cells in the body. Variants of these genes lead to hyperactivity of the PI3Kδ (phosphoinositide 3-kinase delta) pathway, which causes immune cells to fail to mature and function properly, leading to immunodeficiency and dysregulation.^2,3,4 APDS is characterized by a variety of symptoms, including severe, recurrent sinopulmonary infections, lymphoproliferation, autoimmunity, and enteropathy.^5,6 Because these symptoms can be associated with a variety of conditions, including other primary immunodeficiencies, it has been reported that people with APDS are frequently misdiagnosed and suffer a median 7-year diagnostic delay.⁷ As APDS is a progressive disease, this delay may lead to an accumulation of damage over time, including permanent lung damage and lymphoma.^5–8 A definitive diagnosis can be made through genetic testing. APDS affects approximately 1 to 2 people per million worldwide.⁹

About Joenja
Joenja (leniolisib) is an oral small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor approved as the first and only targeted treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older in the U.S., U.K., Australia, Israel, the EU, Canada, and South Korea; in children 4 to 11 years of age who weigh at least 27 kg in the U.S., and for patients 4 years of age and older in Japan.
Leniolisib inhibits the production of phosphatidylinositol-3-4-5-trisphosphate, which serves as an important cellular messenger and regulates a multitude of cell functions such as proliferation, differentiation, cytokine production, cell survival, angiogenesis, and metabolism. Results from a randomized, placebo-controlled Phase III clinical trial demonstrated statistically significant improvement in the coprimary endpoints, reflecting a favorable impact on the immune dysregulation and deficiency seen in these patients, and open label extension data has supported the safety and tolerability of long-term leniolisib administration.^10,11  
Leniolisib is currently under regulatory review for the treatment of APDS in several other countries. Leniolisib is also being evaluated in two Phase II clinical trials in primary immunodeficiencies (PIDs) with immune dysregulation. The safety and efficacy of leniolisib has not been established for PIDs with immune dysregulation beyond APDS.

About Pharming
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biotechnology company that develops and commercializes innovative medicines for people living with rare immune and genetic diseases.

We combine specialized scientific, medical, regulatory and commercial expertise to advance a focused portfolio of approved medicines and development programs that address significant unmet medical needs. Guided by insights from patients and the wider rare disease community, we are dedicated to delivering innovative therapies for some of the most challenging rare diseases.

For more information, visit www.pharming.com and find us on LinkedIn.

  
Forward-looking Statements
This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition”, ‘‘anticipate’’, ‘‘believe’’, ‘‘could’’, ‘‘estimate’’, ‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’, “milestones”, ‘‘objectives’’, ‘‘outlook’’, ‘‘plan’’, ‘‘probably’’, ‘‘project’’, ‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’, ‘‘target’’, ‘‘will’’ and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming’s preclinical studies and clinical trials of its product candidates, Pharming’s clinical and commercial prospects, and Pharming’s expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming’s clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming’s 2025 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming’s actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.

Inside Information
This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

References 

1. FDA. Priority Review. Available at: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review Accessed September 2026.
2. Lucas CL, et al. Nat Immunol. 2014;15(1):88-97.
3. Elkaim E, et al. J Allergy Clin Immunol. 2016;138(1):210-218.
4. Nunes-Santos C, Uzel G, Rosenzweig SD. J Allergy Clin Immunol. 2019;143(5):1676-1687.
5. Coulter TI, et al. J Allergy Clin Immunol. 2017;139(2):597-606.
6. Maccari ME, et al. Front Immunol. 2018;9:543.
7. Jamee M, et al. Clin Rev Allergy Immunol. 2020 Dec;59(3):323-333.
8. Condliffe AM, Chandra A. Front Immunol. 2018;9:338.
9. Vanselow S, et al. Frontiers in Immunology. 2023;14:1208567.  
10. Rao VK, et al Blood. 2023 Mar 2;141(9):971-983.
11. Rao VK, et al. J Allergy Clin Immunol 2024;153:265-74.

For further public information, contact:
Pharming
Michael Levitan, VP Investor Relations & Capital Markets
T: +1 (908) 705 1696
E: investor@pharming.com

Saskia Mehring, Head of Corporate Communications
T: +31 6 28 32 60 41
E: media.relations@pharming.com

Media Relations
Julia Deutsch (Lyra Strategic Advisory on behalf of Pharming)
E: JDeutsch@lyraadvisory.com

Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)
T: +31 6 53 81 64 27

Attachment

• Pharming announces FDA acceptance and Priority Review of sNDA for lower doses Joenja_EN_25SEP2026

Frankfurt listing complements Nasdaq presence and advances the Company’s North Atlantic Critical Metals Corridor strategy

CHARLOTTE, N.C., Sept. 25, 2026 (GLOBE NEWSWIRE) — via IBN – Greenland Mines Ltd (“Greenland Mines” or the “Company”) (Nasdaq: GRML; FSE: HK6), a Greenland-focused mineral resource development company, today announced that its common shares are now listed and trading on the Frankfurt Stock Exchange (“FSE”) under the symbol HK6. The listing provides European investors with an additional venue to access Greenland Mines shares and complements the Company’s principal Nasdaq listing. No new shares are being issued in connection with the Frankfurt listing.

“Greenland Mines is building a transatlantic critical-minerals company, and Frankfurt is a natural next step,” said Bo Møller Stensgaard, President of Greenland Mines Ltd. “Our projects sit at the intersection of Greenland, North America and Europe at a time when allied nations are increasingly focused on securing resilient, responsible sources of rare earths and critical metals. Nasdaq gives us a strong U.S. platform; Frankfurt expands our reach directly into Europe.”

The listing also complements Greenland Mines’ membership in the European Raw Materials Alliance (ERMA) and advances the Company’s broader North Atlantic Critical Metals Corridor strategy, which is intended to connect Greenland’s mineral resources with allied capital, infrastructure, processing pathways and industrial demand across North America and Europe. Greenland Mines is advancing Sarfartoq, its Southwest Greenland rare-earth project focused on neodymium and praseodymium, and Skaergaard, its East Greenland gold, palladium, platinum and critical-metals project.

“Greenland is becoming increasingly important to the economic and security interests of the United States and Europe,” Stensgaard added. “We believe Greenland Mines can be part of that solution—developing strategic resources in an allied jurisdiction and helping build more diversified critical-mineral supply chains on both sides of the Atlantic.”

About Greenland Mines Ltd

Greenland Mines Ltd is a Nasdaq-listed resource development and mining company focused on the development of the Skaergaard Project in southeast Greenland and the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and select midstream processing opportunities, while advancing its assets and broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are often identified by words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “potential,” “could,” “may,” “will,” “should,” “estimate,” “objective” and similar expressions.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties. Many factors could cause actual results to differ materially, including exploration, resource-estimation, metallurgical, engineering, environmental, social, permitting, logistical, infrastructure, financing, commodity-price, market, counterparty and execution risks; the availability and level of participation of advisory board members; changes to planned programs and timelines; the Company’s ability to obtain required approvals and financing; and risks described in documents filed or to be filed with the U.S. Securities and Exchange Commission. No assurance can be given that studies, applications, partnerships, transactions, development decisions or production will occur on the timing contemplated or at all.

Readers should carefully consider these factors and the other risks and uncertainties described in the Company’s SEC filings. All information in this press release is provided as of its date, and the Company undertakes no obligation to update any forward-looking statement except as required by applicable law.

Investor Contact and Corporate Communications:

ir@greenlandmines.com
Website: www.greenlandmines.com

Corporate Communications:

IBN
Austin, Texas
IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Davidson Kempner Capital Management LP
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	easyJet plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	24/09/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?         If it is a cash offer or possible cash offer, state “N/A”	No

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	27 2/7p ordinary (ISIN-GB00B7KR2P84)
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:
(2)   Cash-settled derivatives:	16,302,925	2.15%
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	16,302,925	2.15%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
27 2/7p ordinary	CFD	Increasing a long position	351,355	GBP 6.7000

        
(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii)        Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	25/09/2026
Contact name:	Alex McMillan
Telephone number:	646 282 5805

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

EVANSVILLE, Ind., Sept. 25, 2026 (GLOBE NEWSWIRE) — (NASDAQ: ONB) – Old National Bancorp (“Old National”), the holding company of Old National Bank, today announced the following schedule for its third-quarter earnings release and conference call:

Earnings Release:	Wednesday, October 21, 2026, at approximately 7:00 A.M. ET
Conference Call:	Wednesday, October 21, 2026, at 10:00 A.M. ET
Dial-in Numbers:	U.S. (833) 461-5787; International: (585) 542-9983; Meeting ID 244 307 806
Webcast:	Via Old National’s Investor Relations website at oldnational.com
Webcast Replay:	Available approximately two hours after completion of the call, until midnight ET on October 21, 2027, via Old National’s Investor Relations website at oldnational.com

ABOUT OLD NATIONAL
Old National Bancorp is the holding company of Old National Bank. As the sixth largest commercial bank headquartered in the Midwest, Old National proudly serves clients primarily in the Midwest and Southeast. With approximately $74 billion of assets and $41 billion of assets under management, Old National ranks among the top 25 banking companies headquartered in the United States. Tracing our roots to 1834, Old National focuses on building long-term, highly valued partnerships with clients while also strengthening and supporting the communities we serve. In addition to providing extensive services in consumer and commercial banking, Old National offers comprehensive wealth management and capital markets services. For more information and financial data, please visit Investor Relations at oldnational.com. In 2026, Points of Light named Old National to “The Civic 50” for the third consecutive year – an honor recognizing the 50 most community-minded companies in the United States – and also named Old National the Financials Sector Leader among nominated banks and financial services organizations.

Investor Relations:
Lynell Durchholz
(812) 464-1366
lynell.durchholz@oldnational.com

Media Relations:
Scott Reinhard
(612) 716-0304
scott.reinhard@oldnational.com

At IROS 2026, Seyond will showcase how premium, production-ready LiDAR is supporting robotics as autonomous systems move from specialized applications toward broader real-world deployment

SUNNYVALE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) — As the global robotics community gathers for the 2026 IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS), Seyond is highlighting a transformation already taking place beyond the research lab: robots are becoming an increasingly practical part of everyday life.

Across hospitals, warehouses, sidewalks, and commercial spaces, robots are taking on a growing range of real-world tasks. As the industry moves from prototypes and limited deployments toward broader commercialization, the challenge is no longer simply proving that a robot can navigate autonomously. It is doing so reliably, repeatedly and at meaningful scale.

Seyond is supporting this transition by bringing premium LiDAR technology to applications including healthcare and delivery robots, autonomous forklifts, AMRs, warehouse automation, humanoid robots, and other intelligent robotic platforms.

From Robotics Projects to Real-World Scale

The next wave of robotics growth is not being driven by a single type of robot.

In healthcare environments, autonomous mobile robots can transport medications, supplies, meals, and other materials throughout busy facilities. On sidewalks, delivery robots are bringing food and everyday goods directly to consumers. Across warehouses and logistics facilities, autonomous forklifts and AMRs are moving pallets, packages, and inventory alongside workers.

While these applications are different, they share a common challenge: robots must reliably understand and navigate dynamic environments designed around people.

For Seyond, the opportunity goes beyond supporting one or two robotics projects. As manufacturers move toward larger deployments, they need sensing technology that can meet production requirements without compromising the performance and reliability required for real-world autonomy.

Seyond’s approach is centered on delivering premium LiDAR performance at production scale, balancing sensing performance, quality, integration, reliability, and scalability. With more than one million sensors delivered across its broader business, Seyond brings established manufacturing experience to a robotics market entering its next stage of growth.

Premium Perception, Built for Robotics

Seyond’s robotics portfolio provides high-quality 3D sensing across different form factors, ranges, fields of view, and integration requirements.

The Hummingbird D1R, designed specifically for robotics applications, combines a compact form factor with a 140° × 100° field of view and close-range detection, supporting robotic platforms that need broad environmental awareness within limited installation space.

Seyond is also continuing to expand its robotics sensing portfolio toward even smaller, lighter, and more energy-efficient form factors. These ultra-compact sensing solutions are being developed for emerging space- and power-constrained robotic platforms, where every gram, millimeter, and watt can matter.

As robots become smaller, more capable, and more integrated into everyday environments, Seyond is working to make high-quality 3D perception easier to integrate across an increasingly diverse range of robotic systems.

See Seyond at IROS 2026

At the 2026 IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS), Seyond will showcase its latest robotics sensing technologies and demonstrate how its LiDAR portfolio supports applications ranging from industrial automation and autonomous material handling to emerging robots designed to operate alongside people.

Visitors can meet the Seyond team at Booth 928 to explore how high-performance LiDAR can support the next generation of intelligent robotic systems.

The future of robotics will not be defined by a handful of prototypes, but by robots performing useful work at meaningful scale across the places where people live, work, receive care, and move through their day. Seyond is building the sensing technology to help make that transition possible.

About Seyond

Seyond is a global provider of advanced LiDAR solutions for automotive, robotics, and intelligent infrastructure applications. Focused on performance, reliability, and scalability, Seyond’s LiDAR technologies enable real-world autonomy across diverse operating environments. The company is committed to accelerating the adoption of safe, intelligent, and connected systems through next-generation 3D sensing.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/72d1cb74-198b-479a-a1c6-a529897ed357

CONTACT: PR Contact:
Seyond Marketing Team
PR@seyond.com

MONTREAL, Sept. 25, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 345 on the 2026 Report on Business magazine’s ranking of Canada’s Top Growing Companies.

Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Knight earned its spot with three-year growth of 53%.

“We’re honored to be recognized as one of Canada’s Top Growing Companies by Report on Business for the sixth consecutive year,” said Samira Sakhia, President and CEO of Knight. “This recognition belongs to our team across Canada and Latin America. Their focus and disciplined execution continue to drive Knight’s growth. We remain committed to bringing innovative products to physicians and improving the health of the patients they serve. With over 50 product launches completed or planned across Canada and Latin America, we are well positioned to build on this momentum.”

Canada’s Top Growing Companies is an editorial ranking that was launched in 2019 to celebrate the achievements of innovative businesses in Canada. To qualify for this voluntary program; companies had to complete an in-depth application process and fulfill revenue requirements. In total, 375 companies earned a spot on this year’s ranking.

The full list of 2026 winners along with editorial coverage is published in the October issue of Report on Business magazine. The list is also published online here.

“Our annual ranking of Canada’s Top Growing Companies celebrates the innovation, ambition and resilience of businesses across the country, and we’re always excited to share as many of these standout stories as we can – including insight from the entrepreneurs themselves on how other companies can succeed, too.” says Dawn Calleja, editor of Report on Business magazine.

“The Globe and Mail congratulates the winners of Canada’s Top Growing Companies 2026 on this exceptional achievement,” says Andrew Saunders, president and CEO of The Globe and Mail. “Each of these organizations has shown an extraordinary ability to adapt, innovate and grow amid ongoing change. Their achievements reflect the ingenuity and determination of Canadian entrepreneurs and business leaders who are helping shape the future of our economy.”

About The Globe and Mail

The Globe and Mail is Canada’s foremost news media company, leading the national discussion and causing policy change through brave and independent journalism since 1844. With our award-winning coverage of business, politics and national affairs, The Globe and Mail newspaper reaches 6.1 million readers every week in our print or digital formats, and Report on Business magazine reaches 2.7 million readers in print and digital every issue. Our investment in innovative data science means that as the world continues to change, so does The Globe. The Globe and Mail is owned by Woodbridge, the investment arm of the Thomson family.

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

Investor Contact:
Knight Therapeutics Inc.
Samira Sakhia		Arvind Utchanah
President & Chief Executive Officer		Chief Financial Officer
T: 514.484.4483		T: 514.484.4483
Email: IR@knighttx.com		Email: IR@knighttx.com
Website: www.knighttx.com		Website: www.knighttx.com

This press release was published by a CLEAR® Verified individual.

MISSISSAUGA, Ontario, Sept. 25, 2026 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been named as one of Canada’s Top Growing Companies for 2026 by The Globe and Mail’s Report on Business magazine. BioSyent ranked 343 on the list based on its three-year revenue growth of 54% (2022 – 2025) and is listed in the ‘Consumer’ category.

“We are very proud to have been recognized as one of Canada’s Top Growing Companies,” said René Goehrum, President and CEO of BioSyent. “With the support of our team and the continued trust of patients and healthcare providers, we have continued to execute on one of BioSyent’s key strategic priorities of profitable growth, with Q2 2026 marking the 64^th consecutive profitable quarter for the Company.”

The full 2026 ranking of Canada’s Top Growing Companies is available online at globeandmail.com and will appear in the October issue of Report on Business magazine.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty healthcare products company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its Pharmaceutical and Oral Health businesses, both in Canada and internationally.

As of the date of this press release, the Company has 11,232,335 common shares outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web: www.biosyent.com

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

SHANGHAI, China, Sept. 25, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, has released its 2026 interim report, highlighting continued progress in its “AI + Chronic Disease Services” strategy as the Company advances its positioning as a full-lifecycle personal health service partner.

In the first half of 2026, Fangzhou recorded revenue of RMB1.8245 billion, up 22.2% year-on-year, while adjusted net profit increased 6.4% to RMB18.7 million. The Company’s cumulative registered users exceeded 59.8 million, with average monthly active users rising 23.1% to 14.7 million. Its network of registered physicians expanded to 282,000.

Fangzhou continued to accelerate the deployment of AI across chronic disease services, addressing persistent challenges in out-of-hospital management, including treatment adherence, patient follow-up and care costs. Built on its proprietary “XingShi” Large Language Model (“XS LLM”), its AI Health Manager and AI Medication Assistant provide 24/7 support, medication reminders and personalized health management based on patients’ evolving needs, helping shift chronic care from passive response toward proactive, continuous support.

On the physician side, AI pre-consultation, AI-assisted diagnosis and the AI Academic Assistant help reduce repetitive administrative workloads and improve service efficiency. Digital tools also support post-consultation follow-up, allowing professional medical services to reach more patients. Internally, Fangzhou has extended AI applications into supply-chain management, including inventory allocation and last-mile delivery, to improve operational efficiency.

The Company also continued strengthening the industry ecosystem underpinning its healthcare services. During the period, Fangzhou worked with more than 1,800 suppliers and 1,000 pharmaceutical companies, while prescription drugs accounted for 83.1% of platform GMV. Strategic collaborations with pharmaceutical companies, including Youcare Pharmaceutical and Tenry Pharma, supported the launch of innovative medicines, helping connect pharmaceutical innovation with patients through Fangzhou’s digital healthcare infrastructure.

Leveraging its patient network and digital engagement capabilities, Fangzhou is also expanding its role as a digital collaboration partner for pharmaceutical companies. Across key chronic disease specialties, the platform integrates medication guidance, patient education and full-course disease management into everyday services, supporting broader access to innovative treatments while strengthening its professional chronic care capabilities.

In the second half of 2026, Fangzhou will further advance its strategy as a full-lifecycle personal health service partner, expanding the XS LLM and its portfolio of AI-powered services across more healthcare scenarios. The Company will also deepen collaboration with pharmaceutical partners and strengthen specialty-care capabilities, helping to build a reliable, patient-centered health service ecosystem that supports patients throughout their health journey.

About Fangzhou Inc.

Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 59.8 million registered users and 282,000 physicians (as of June 30, 2026). The Company specializes in delivering tailored medical care and AI‑enabled precision medicine solutions. For more information, visit https://investors.jianke.com.

Media Contact

For further inquiries or interview requests, please contact:

Xingwei Zhao
Director of Public Relations
Email: pr@jianke.com

Disclaimer: This press release contains forward‑looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements.